Lipocine Updates Corporate Presentation in Recent 8-K Filing

Lipocine Inc. has disclosed in its recent 8-K filing with the Securities and Exchange Commission that the company has made changes to its corporate presentation utilized during engagements with investors, analysts, and other relevant parties. The updated presentation has been officially submitted as Exhibit 99.1 alongside the filing.

Based on the filing, Lipocine Inc., a Delaware-based entity with a registration number of 001-36357 and an Employer Identification Number of 99-0370688, currently operates from its principal executive offices situated at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah, with a corresponding ZIP code of 84108. For communication purposes, interested individuals can reach out via the following telephone number: (801) 994-7383.

The common stock of Lipocine Inc., with a par value of $0.0001 per share and trading under the symbol “LPCN” on The NASDAQ Stock Market LLC, is registered pursuant to Section 12(b) of the Act. As per the securities filing, Lipocine Inc. does not qualify as an emerging growth company as defined by Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

According to the report, the company has updated its corporate presentation as a notable event and has provided the presentation as Exhibit 99.1 within the filing. Additionally, the filing includes the incorporation of the Cover Page Interactive Data File as Exhibit 104.

Mahesh V. Patel, the President, and Chief Executive Officer of Lipocine Inc., has duly signed the document on behalf of the organization as required by the Securities Exchange Act of 1934. The signed report is dated February 11, 2025.

The updates within the corporate presentation signify Lipocine Inc.’s commitment to ensuring transparent and comprehensive communication with stakeholders as part of its ongoing business operations.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lipocine’s 8K filing here.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.